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Abstract
Background: In Major Depressive Disorder (MDD), the traditional belief of a delayed onset of antidepressants’
effects has lead to the concept of current guidelines that treatment durations should be between 3-8 weeks
before medication change in case of insufficient outcome. Post hoc analyses of clinical trials, however, have shown
that improvement usually occurs within the first 10-14 days of treatment and that such early improvement
(Hamilton Depression Rating Scale [HAMD] decrease ≥20%) has a substantial predictive value for final treatment
outcome. Even more important, non-improvement (HAMD decrease <20%) after 14 days of treatment was found
to be highly predictive for a poor final treatment outcome.
Methods/Design: The EMC trial is a phase IV, multi-centre, multi-step, randomized, observer-blinded, actively
controlled parallel-group clinical trial to investigate for the first time prospectively, whether non-improvers after 14
days of antidepressant treatment with an early medication change (EMC) are more likely to attain remission
(HAMD-17 ≤7) on treatment day 56 compared to patients treated according to current guideline recommendation
(treatment as usual; TAU). In level 1 of the EMC trial, non-improvers after 14 days of antidepressant treatment will
be randomised to an EMC strategy or TAU. The EMC strategy for this study schedules a first medication change on
day 15; in case of non-improvement between days 15-28, a second medication change will be performed. TAU
schedules the first medication change after 28 days in case of non-response (HAMD-17 decrease <50%). Both
interventions will last 42 days. In levels 2 and 3, EMC strategies will be compared with TAU strategies in improvers
on day 14, who experience a stagnation of improvement during the course of treatment. The trial is supported by
the German Federal Ministry of Education and Research (BMBF) and will be conducted in cooperation with the
BMBF funded Interdisciplinary Centre Clinical Trials (IZKS) at the University Medical Centre Mainz and at six clinical
trial sites in Germany.
Discussion: If the EMC strategies lead to significantly more remitters, changes of clinical practice, guidelines for the
treatment of MDD as well as research settings can be expected.
Trial Registration: Clincaltrials.gov Identifier: NCT00974155; EudraCT: 2008-008280-96.
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Major depressive disorder (MDD) is a psychiatric illness
in which mood, thoughts and behavioural patterns are
impaired for long periods. The illness distresses the per-
son and impairs his or her social functioning and quality
of life. MDD is characterized by marked sadness or a
loss of interest or pleasure in daily activities, and is
accompanied by weight change, sleep disturbance, fati-
gue, difficulty concentrating, physical impairment and a
high suicide rate [1].
Prevalence of MDD
MDD is a highly prevalent, often chronic or episodic
lifelong disorder. The recent large, community-based
European Study of the Epidemiology of Mental Disor-
ders (ESEMeD) found major depression being the most
prevalent psychiatric disorder with lifetime and 12-
months prevalence rates as high as 12.8 and 3.9%,
respectively, in the total population. In females the pre-
valence rates were almost twice as high as compared to
men (lifetime: 16.5% vs. 8.9%, resp.; 12-months: 5.0% vs.
2.9%, resp.) [2]. In the United States (US) the recent
National Comorbidity Survey Replication (NCS-R)
found even higher lifetime and 12-months prevalence
rates of 16.2% and 6.6%, resp. [3].
Impairment by MDD
Many studies showed that nearly all patients with MDD
suffer from mild to very severe impairment in several
domains of life like physical activities, social activities, or
occupational responsibilities. E.g., in the above men-
tioned NCS-R [3] respondents with 12-month MDD
reported a mean of 35.2 days in the past year in which
they were totally unable to work or carry out their nor-
mal activities because of their depression. Following
analyses of the World Health Organisation (WHO),
MDD persistently belongs to the most disabling diseases
worldwide. In 1990, unipolar depressive disorders were
the 4
th leading cause of disability adjusted life years
(DALYs), a measure reflecting the burden of diseases,
injuries, and risk factors based on years of life lost due
to premature mortality (YLL) and years of life lived in
less than full health (YLD). Unipolar depressive disor-
ders have been projected to be the 2
nd leading cause of
DALYs by the year 2020. A recent re-analysis confirmed
this 4th rank for unipolar depressive disorders for the
year 2002 as well as the projection as the 2nd leading
cause of DALYs for the year 2030, only exceeded by
HIV/AIDS. [[4], and references inside].
Costs associated with MDD
MDD produces substantial costs through hospital
admissions, outpatient care and productivity loss as a
result of depression-related morbidity, suicide, and other
relevant parameters. For Europe (28 countries with
approx. 466 million population) the annual costs for
depression have been estimated at € 118 billions in
2004. Direct costs alone totalled € 42 billions, comprised
of outpatient care (€ 22 billions), drug cost (€ 9 billion)
and hospitalisation (€ 10 billion). Indirect costs were
estimated at € 76 billions. This makes depression the
most costly brain disorder in Europe [5]. Following
recent analyses, the USA (approx. 270 million popula-
tion) was burdened in the year 2000 by $ 26.1 billion
direct costs, $ 5.4 billion suicide-related mortality-costs
and $ 51.5 billion workplace costs, resulting in a total of
$ 83.1 billion [6].
Outcome of MDD treatment with current strategies is
insufficient and more efficient ADs are not to be
expected within the next years
The above mentioned data clearly indicate the utmost
importance of effective treatments for MDD. The use
of antidepressants for the treatment of MDD is well
established. However, effect sizes of currently available
antidepressants are rather small than medium [7,8].
Drug-placebo difference in efficacy of antidepressants
increases with baseline severity, but remains relatively
small even for severely depressed patients [7]. Large
effectiveness trials like the Sequenced Treatment Alter-
native to Relieve Depression (STAR*D) study with
representative patient populations clearly show that
treatment outcome remains disappointing with remis-
sion rates of maximal 37% [[9], and references inside].
Antidepressants vary in side effect profile and safety,
but hardly with respect to efficacy: e.g. for the 2
nd gen-
eration antidepressants like selective serotonin reup-
take inhibitors, selective serotonin and noradrenaline
reuptake inhibitors and the a2-antagonist mirtazapine
differences in efficacy have been reported, but only of
small effect size [10,11]. Finally, new developments
such as the substance P- and CRH-receptor antago-
nists have failed to prove antidepressant efficacy and
the melatonin agonist agomelatine did not show better
efficacy than established antidepressants. Thus, out-
comes of currently available strategies for MDD treat-
ment are disappointing and more efficient
antidepressants are not expected in the next years.
Hence, it is sensible to develop new strategies to
increase remission rates in acutely depressed patients
by means of the antidepressants we currently have.
Treatment optimisation in the early course of treatment
is not implemented in clinical guidelines
A second unmet need of patients suffering from MDD is
a shortening of the time to remission. Common clinical
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a delay of several weeks. This view stems mainly from
two sources: first, controlled clinical trials aiming to pro-
vide evidence for an antidepressants’ efficacy usually
compare the active compound with placebo. By compar-
ing mean scores of rating scales as measures for depres-
sive symptomatology using repeated measurement
analysis of variance, a significant difference between
active treatment and placebo usually is detected from
week 2-4 and onward. This statistical time lag has long
been misinterpreted as indicating a delayed onset of
action of antidepressants. Second, pattern analysis [12,13]
have suggested that persistent or “true” drug response
occurs mainly in the later course of treatment, i.e., week
3-4, while response occurring in the first two weeks was
assumed to be unstable and due to placebo effects. Taken
together, these interpretations led to the hypothesis of a
delayed action of antidepressants and have had substan-
tial impact on clinical practice. Current international and
national guidelines for the treatment of MDD usually do
not contain recommendations for optimisation strategies
(re-assessment of diagnosis, dose adjustments, change of
treatment, etc.) in the early course of treatment. The
recommended treatment duration until insufficient out-
come can be assumed and treatment should be optimised
is between 2-4 weeks [14], 3-4 weeks [15,16], 4-6 weeks
[17], or 4-8 weeks [18]. Moreover, the low concordance
between guidelines reflects substantial uncertainties in
the appropriate duration of treatment until the identifica-
tion of insufficient outcome and no guideline recommen-
dation is based on prospective trials, but only on
retrospective data analyses.
True drug response can be observed within 14 days of
antidepressant treatment
Challenging the idea of a delayed onset of antidepres-
sants’ action, there is a substantial body of evidence
from many retrospective studies with virtually all groups
of antidepressants strongly suggesting that a true drug
response can be observed within the first 14 days of
treatment. [19-27]. E.g., a recent large meta-analysis [22]
with data from 4076 patients randomised to active anti-
depressants and 3045 patients randomised to placebo
showed that verum-treated patients were more likely to
experience clinical response by 2 weeks or even 1 week
of treatment than placebo-treated patients. A further
meta-analysis [21] comprising 3418 placebo- and 5158
verum-treated patients found nearly identical time
courses of improvement on placebo and active medica-
tion: 60.2% and 61.6%, resp., of the improvement
occurred within the first 2 weeks. The differences
between drug and placebo were most pronounced dur-
ing the first 2 weeks of treatment and diminished
thereafter.
Early improvement is predictive for final outcome
The occurrence of improvement of depressive symptoms
in the early course of treatment has been identified as
being highly predictive for final treatment outcome. Nier-
enberg and colleagues have reported that >50% of
patients who eventually respond to fluoxetine treatment
started to improve during the first 2 weeks of treatment
and that early non-response to fluoxetine treatment pre-
dicted poor 8-weeks outcomes [[19], and references
Inside]. Katz and colleagues reported on a randomised
controlled trial (RCT) in which patients were treated
with the selelctive serotonin reuptake inhibitor paroxe-
tine, the tricyclic antidepressant desipramine or placebo
[20]. In this study, early treatment-specific behavioural
changes occurred that were not observed in the placebo-
group, and these changes were highly predictive of ulti-
mate clinical response to antidepressant therapy. In mul-
tiple studies between 1993 and 2007, Stassen and
colleagues analysed individual time courses of response
in depressed patients treated with various antidepressants
[[24], and references inside]. A model-finding study with
repeated HAMD17 assessments during a 1-week placebo
run-in showed that the observed fluctuations did not
exceed 15% of baseline score. In consequence, onset of
improvement (which models onset of action) has been
defined as a 20% baseline score reduction in accordance
with clinical practice in which a 4-point HAMD17 reduc-
tion (= 20% for a HAMD17 score of 20) is regarded as
clinically relevant. Each of their analyses revealed that
patients with improvement during the first 2 weeks (=
early improvement) of antidepressant treatment showed
substantial response at study endpoint. A recent meta-
analysis of 2,848 patients with MDD confirmed previous
analyses showing that early improvers were far more
likely to become responders than patients without early
improvement (pooled OR = 9.25, 95%-CI = 7.79-10.98)
[24]. In separate analyses, Szegedi and colleagues exam-
ined early improvement in a randomised controlled trial
comparing mirtazapine and paroxetine in MDD patients
[25]. Improvement (HAMD17 score reduction ≥20%)
occurred in a majority of patients within 2 weeks of treat-
ment, and this improvement was a highly sensitive pre-
dictor of later stable response (HAMD17 score reduction
≥50% at week 4 and onward) and stable remission
(HAMD17 score ≤7a tw e e k4a n do n w a r d )f o rb o t h
drugs. Less than 10% of patients who had not improved
after 2 weeks of treatment became stable responders or
remitters over the course of the study. Szegedi and col-
leagues recently extended their research to 41 clinical
trials with 6,562 MDD patients treated with mirtazapine,
serotonine reuptake inhibitors, tricyclics, venlafaxine and
placebo [26]. Again, early improvement predicted stable
response and stable remission with high sensitivity (>80%
and 87%, resp.). Only 11% and 4.1% of patients, who did
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responders or stable remitters, respectively. The finding
of early improvement being highly predictive for later
outcome resulted in the idea that an effective antidepres-
sant treatment triggers and maintains conditions neces-
sary for recovery from the disorder [24]. It has been
suggested that affectively ill patients possess a biological,
“resilience"-like componentt h a tc o n t r o l sr e c o v e r yf r o m
depression to a major extent. Once triggered, recovery
seems to follow - independent of pharmacologic differ-
ences of the triggers - a uniform pattern of course. Con-
sequently, the vast majority of patients showing a
favourable later outcome experience the respective onset
within the first 2 weeks of treatment. Inversely, non-
improvement after 2 weeks of treatment seems to indi-
cate that a selected antidepressant did not trigger the
resilience-like component and has strongly limited
chances to do so, even if continued in the course of treat-
ment. Based on these findings in retrospective analyses,
leading experts in this field have repeatedly recom-
mended the outcome evaluation in the early course of
treatment as well as the consideration of early symptom
changes in clinical decision making [22,24-27].
Methods/Design
Trial objectives
The primary objective of the trial is to compare effec-
tiveness of EMC with TAU in the treatment of Major
Depressive disorder (MDD) in non-improvers on day 14
(level 1 of The EMC Trial). The secondary objectives of
the trial are i) to compare speed of recovery from MDD
between EMC and TAU in non-improvers on day 14
(level 1 of The EMC trial), ii) to compare the side effect
profile and safety of EMC and TAU in non-improvers
on day 14 (level 1 of The EMC trial), iii) to compare
changes in quality of life under EMC and TAU in non-
improvers on day 14 (level 1 of The EMC trial), iv) to
compare effectiveness, speed of recovery from MDD,
changes in quality of life and side effect profile in sub-
groups of improvers on day 14 (levels 2 and 3 of The
EMC trial).
Design
For an overview of the design of the EMC trial, see
Figure 1.
Level 1
After inclusion and appropriate washout of possible pre-
medication with other antidepressants, patients will
receive the selective serotonin reuptake inhibitor escita-
lopram for 14 days. The dose will be escalated to the
participant’s highest tolerable dose (max. 20 mg/day).
Non-improvers, defined by a decrease of <20% on the
17-item Hamilton Depression Rating Scale (HAMD17)
[28] between day 0 and day 14 will be randomly
assigned to EMC 1 or TAU 1, which both will last 42
days. Patients in the EMC 1 arm will be switched on
day 15 to the dual acting selective serotonergic and nor-
adrenergic antidepressant venlafaxine. The dose will be
escalated to the participant’s highest tolerable dose
(max. 375 mg/day). After 14 days of venlafaxine treat-
ment, non-improvers (HAMD17 decrease <20% from
day 14-28) will have an augmentation therapy with
lithium (plasma level range 0.6-0.8 mmol/l) for 28 days.
For improvers under venlafaxine treatment (HAMD17
decrease ≥20% from day 14-28), venlafaxine will be con-
tinued for 28 days. Patients randomised to TAU 1 will
be treated according to current guidelines, which
recommend 28 days of unchanged therapy and use the
response criterion (HAMD17 decrease ≥50%) to guide
further strategy. Thus, escitalopram will not be changed
on day 15, but continued to day 28. In case of response
on day 28, escitalopram will be continued for further 28
days. In case of non-response on day 28 (HAMD17
decrease <50%), escitalopram will be switched to venla-
faxine (max. 375 mg/day), which will be administered
for 28 days.
Level 2
Improvers (HAMD17 decrease ≥20%) on day 14 will con-
tinue treatment with escitalopram at the highest tolerable
dose (max. 20 mg/d). Non-responders on d28 (HAMD17
decrease of <50% between d0-d28) will be treated accord-
ing to current guidelines and will be switched to venla-
faxine. The dose of venlafaxine will be escalated to the
participant’s highest tolerable dose (max. 375 mg/day).
After 14 days of venlafaxine treatment (d29-d42), non-
improvers 2 (HAMD17 decrease <20% between d28-42)
will be randomly assigned to EMC 2 or TAU 2, which
both will last 14 days. Patients in the EMC 2 arm will
have an augmentation therapy with lithium (plasma level
range 0.6-0.8 mmol/l) for 14 days. Patients randomised
to TAU 2 will be treated according to current guidelines,
which do not contain recommendations for an optimisa-
tion of treatment two weeks after medication switch.
Therefore, these patients will continue venlafaxine treat-
ment until day 56. For IML2 under venlafaxine treatment
(HAMD17 decrease ≥20% between d28-d42), venlafaxine
will be continued for 14 days at the participant’sh i g h e s t
tolerable dose.
Level 3
Responders on d28 (HAMD17 decrease of ≥50%
between d0-28) will continue treatment with escitalo-
pram at the highest tolerable dose. Remitters on d28
(HAMD17 sum score ≤7) will be regarded as respon-
ders. After further 14 days of escitalopram treatment
(d29-42), non-improvers 3 (HAMD17 decrease <20%
between d28-42) will be randomly assigned to EMC 3
or TAU 3, which both will last 14 days. Remitters on
d42 (HAMD17 sum score ≤7) will be regarded as
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EMC 3 arm will be switched to venlafaxine. The dose of
venlafaxine will be escalated to the participant’sh i g h e s t
tolerable dose (max. 375 mg/day). Patients randomised
to TAU 3 will be treated according to current guide-
lines, which do not contain recommendations for an
optimisation of treatment in case of non-improvement
after an initial response. For IML3 with continued esci-
talopram treatment (HAMD17 decrease ≥20% between
d28-42), escitalopram will be continued for 14 days at
the participant’s highest tolerable dose.
Trial duration
The duration of this trial is expected to be 36 months.
The subject recruitment started in September 2009; the
end of the recruitment period is planned for February
2012. The actual overall trial duration or subject recruit-
ment period may vary from this time period.
Primary endpoint
Remission from MDD, defined as a HAMD17 sum
score ≤7 [29] on day 56, is the primary endpoint and
will be analyzed only for non-improvers on day 14
( l e v e l1o ft h eE M CT r i a l ) .Remission denominates the
complete absence of residual clinical symptoms and
functional impairments. It is well established that
symptomatic response without remission is associated
with a worse prognosis and continuing functional dis-
ability. For these reasons, acute-phase treatment aims
at symptom remission, not just response. Remission
from MDD has become the most important outcome
parameter in trials investigating the effectiveness of
Figure 1 Design of The EMC Trial. Abbreviations: d = study day; ESC = Escitalopram; LI = Lithium; t = time point; VEN = Venlafaxine; EMC =
early medication change group; TAU = treatment as usual group; IML2 = improver group level 2; IML3 = improver group level 3. Definitions:
improvement = reduction of HAMD17 sum score ≥20% in a specified time span, e.g. between time point (t) 0 and t1; non-improvement =
reduction of HAMD17 sum score <20%; response = reduction of HAMD17 sum score ≥50%; non-response = reduction of HAMD17 sum score
<20%. Grey boxes indicate randomized groups (non-improver t0-t1; non-improver 2/t2-t3; non-improver 3/t2-t3).
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scale is one of the most widely used clinician rated
instruments for the assessment of mood disturbances,
has been internationally validated and proven to be
sensitive to change.
Secondary endpoints
Response, defined as a HAMD17 sum score decrease
≥50% on day 56. Response is generally regarded as a
clinically relevant treatment outcome and commonly
used in clinical trials. A reduction of ≥50% from base-
line score is the usual definition. Furthermore, we will
asses the following secondary endpoints: absolute
change of HAMD17 sum score between d0 and d56;
remission and response, defined as a sum score ≤11 on
the 30-item Inventory of Depressive Symptomatology
(IDS-C30) and 50% baseline score reduction, respec-
tively, on day 56. The IDS is available in the clinician
(IDS-C30) and the self-rated version (IDS-SR30); remis-
sion is defined as a sum score ≤11, response as a 50%
baseline score reduction. The IDS-C30 is sensitive to
changes in depressive severity; evidence of acceptable
psychometric properties of the IDS scales and correla-
tions with other established rating scales (e.g.,
HAMD17) are available http://www.ids-qids.org. The
self-report version was developed to be an “easy to use”
severity measure, providing a potentially more time effi-
cient alternative to clinician rated instruments in both
clinical or research settings.
In levels 2 and 3 of the EMC trial, further secondary
endpoints will be assessed: time to remission and time
to response according to IDS and HAMD17; remission
from MDD, defined as HAMD17 sum score ≤ 7o nd a y
56 (in subgroups of improvers on day 14 entering level
2 or level 3 of The EMC trial); absolute change in SF-12
subscales “physical component score” and “mental com-
ponent score” (day 56-day 0); occurrence of adverse
events, UKU ratings [30] at all visits and relevant labora-
tory data (routine laboratory, therapeutic drug
monitoring).
Selection and withdrawal of subjects
In order to acquire a sample representative of inpatients
with MDD, the EMC trial has broad inclusion criteria
that allow enrolment of both adult and elderly patients,
moderately to very severely depressed patients as well as
MDD patients with other psychiatric comorbid disor-
ders. The EMC trial prospectively enrols inpatients of
the participating centres, which assures the recruitment
of help-seeking patients and provides highest adherence
and compliance to protocol treatment. Hospitalisation
of patients can occur after referral from the treating
general practitioner, from the treating psychiatrist in the
outpatients sector, from another hospital (e.g. after
treatment in an intensive care unit in case of suicide
attempt) or immediately after consultation of the
departments’ physician in charge. In general, the indica-
tion for emergent hospitalisation in a department of
psychiatry is given in case of acute suicidality or risk of
acute endangerment for others as well as in case of pro-
minent psychotic symptoms. Typical indications for hos-
pitalisation of patients with Major Depression are a
severity of depression exceeding the capacity of outpati-
ent care including suicidality, the risk of isolation due to
depression and other severe psychosocial factors, life cir-
cumstances, which significantly impair the treatment
success, resistance to outpatient treatment, high risk for
(further) transition into chronicity of the disease. No
subject will be allowed to be enrolled in this trial more
than once.
Inclusion criteria
Subjects meeting all of the following criteria will be con-
sidered for admission to the trial:
￿ Major Depressive Disorder (MDD), first episode or
recurrent, according to DSM-IV
￿ AH A M D 1 7s c o r eo f≥18 pts. Although there are
different cut-offs for mild to moderate depression vary-
ing between 13/14-17/18 pts., the cut-off of ≥18 pts. is
the most often used in clinical trials and assures the
inclusion of at least moderately depressed patients.
￿ Age between 18 and 65 years and age ≤ 60 years at
the time of the first depressive episode. This age range
assures the inclusion of patients with early-onset depres-
sion in contrast to late-onset depression, for which dif-
ferent pathophysiological mechanisms have been
suggested. In addition, the vast majority of studies on
the predictive value of early improvement included
patients aged ≤ 65 years.
￿ Ability of subject to understand character and indivi-
dual consequences of clinical trial.
￿ Signed and dated informed consent of the subject
must be available before start of any specific trial
procedures.
Exclusion criteria
Subjects presenting with any of the following criteria
will not be included in the trial:
￿ Acute risk of suicide needing an intervention not
comprised by protocol treatment (e.g. electroconvulsive
therapy)
￿ Patients with a lifetime DSM-IV diagnosis of demen-
tia, schizophrenia, schizoaffective disorder, bipolar disor-
der (this group is excluded because they have a
psychiatric condition that requires a different
treatment).
￿ Patients with a current DSM-IV diagnosis of post-
traumatic stress disorder, obsessive-compulsive disorder,
anxiety disorder, or eating disorder and the requirement
of a treatment not comprised by protocol treatment.
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ing acute detoxification.
￿ Depression due to organic brain disorder, e.g. Multi-
ple Sclerosis and Parkinson’s Disease
￿ Women who are pregnant, breastfeeding or planning
to become pregnant during the trial (a pregnancy test
will be performed at screening visit)
￿ W o m e nw h oa r en o ts t e r i l eb ys u r g e r yo rf o rm o r e
than two years postmenopausal or women with child-
bearing potential who not practicing a medically
accepted contraception during trial (reliable contracep-
tion are systemic contraceptives (oral, implant, injec-
tion), diaphragm or condoms with spermicide, sexual
abstinence).
￿ Patients currently taking antidepressant medication,
which has been started within the 2-4 weeks prior to
study, begin and a continuation of this antidepressant
medication is clinically indicated.
￿ A clear history of non-response to an adequate treat-
ment trial in the current major depressive episode to
any protocol antidepressant. A “clear history of non-
response” has to be assumed, when the following criteria
are fulfilled:
◦ ad Escitalopram: Treatment with a mDDD ≥15
mg/d for 4 weeks or CPL 15-80 ng/ml for four weeks
without response, i.e. a symptom reduction ≥50%
between start and end of treatment.
◦ ad Venlafaxine: Treatment with a mDDD ≥300
m g / df o r4w e e k so rC PL 195-400 ng/ml for four
weeks without response, i.e. a symptom reduction
≥50% between start and end of treatment;
◦ ad Lithium: Treatment with CPL 0.6-0.8 mol/l Li
+
for four weeks without response, i.e. a symptom
reduction ≥50% between start and end of treatment.
￿ History of medical or psychological condition, meta-
bolic dysfunction, physical examination finding, or clini-
cal laboratory finding giving reasonable suspicion of a
disease or condition that contraindicates the use of an
investigational drug or render the patient at high risk
from treatment complications.
￿ History of hypersensitivity to the investigational
medicinal product or to any drug with similar chemical
structure or to any excipient present in the pharmaceu-
tical form of the investigational medicinal product.
￿ Clinically significant or unstable medical or surgical
condition that may preclude safe and complete study par-
ticipation. Such conditions may include gastrointestinal,
cardiovascular, vascular disease, pulmonary/respiratory,
hepatic impairment, renal, metabolic diseases, endocrino-
logical, neurological, immune-deficiency, haematopoietic
disease, or malignancies as determined by medical history,
physical examination, or laboratory tests.
￿ Participation in other clinical trials during the pre-
sent clinical trial or within the last 6 months.
￿ Medical or psychological condition that would not
permit signing of informed consent.
Withdrawal criteria
Subjects can be withdrawn their consent at their own
request without given reasons at all time during the
trial. This will be without disadvantages for the subject.
However, the investigator should try to perform a final
visit to get concluding findings of investigation. Partici-
pants withdrawn from the study will not be replaced,
regardless of the reason for withdrawal. The participa-
tion in this study may be discontinued due to any of
the following reasons: i) at their own request; ii) for
safety reasons at the request of the Sponsor; iii) request
of a regulatory agency; iv) significant adverse events
related to the therapy (participants will be followed up
for treatment response and safety); v) participant is
non-compliant or not sufficiently compliant with the
study procedures/study protocol; vi) if, in the investiga-
tor’s opinion, continuation of the trial would be detri-
mental to the subject’s well-being; vii) participant needs
a medication not allowed in the protocol during the
study; viii) any clinically significant change in partici-
pant’s pre-study medical condition; ix) positive preg-
n a n c yt e s t( s a f e t yf o l l o w - u pu pt oa n di n c l u d i n gt h e
premature termination of the pregnancy or delivery of
the child and assessments of effects on the foetus or
child). The Investigator decides about withdrawal of
subjects from the clinical trial in case of occurrence of
criteria mentioned above. In all cases, the reason for
withdrawal must be recorded in the case record file and
in the subject’s medical records. In case of withdrawal
of a subject at his/her own request, as far as possible
the reason should be asked for and documented. The
subject must be followed up and as far as possible all
examinations scheduled for the final trial day should be
performed and documented. All ongoing serious adverse
events of withdrawn subjects have to be followed up
until no more signs and symptoms are verifiable or the
health condition of the subject has stabilized, but no
longer than 6 months after subjects discontinuation
from the trial.
Measures taken to minimize/avoid bias
Randomisation
Randomisation lists stratified by level (1 to 3) and centre
will be generated by the IZKS. The randomisation ratio
will be 1:1 using block randomisation. Randomisation is
not stratified by severity of depressive symptoms or
duration of the disease. The very close relation between
early non-improvement and final treatment failure dur-
ing antidepressant treatment has been identified in sev-
eral clinical studies covering a broad range of severities
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We identified the same relation in patients with mild
major, minor or subsyndromal depression (Tadić et al.
2010). Taken together, the currently available data sup-
port the idea that early non-improvement is a general
marker of inefficacy of antidepressant treatment and
that this very close relation between early non-improve-
ment and final failure of treatment response exists inde-
pendently of severity or duration of depression. Centre
effects are not to be expected; in the STAR*D trial [[9],
and refs. Inside] remission and response rates did not
differ between 18 primary and 23 psychiatric care set-
tings. Nevertheless, centre effects will be analysed post
hoc. A web based randomisation tool developed by
IZKS Mainz will be used within this trial allowing inves-
tigators to randomize patients via a secure web inter-
face. Role specific access rights and the need to confirm
all details necessary for stratified randomisation (level
and centre) are incorporated within the tool and will
reduce the risk of misuse and unintended randomisa-
tions. The randomisation tool “e-randomiXer” has been
released for use within the study after all components
implemented specifically for The EMC Trial have been
sufficiently tested.
Blinding
To prevent assessment bias, trained raters will be
blinded to treatment. The training was carried out using
five videotaped interviews using the HAMD17 and three
interviews using the IDS-C30. All patients had given
informed, written and videotaped consent prior to the
interview. Thirteen raters from six trial sites were
trained. Prior to the training the video tapes were rated
by two experienced raters. Rating agreement (accuracy)
of the individual items of HAMD17 and IDS-C30 with
the expert ratings as well as the intra class correlation
(ICC) were high (detailed results will be presented
elsewhere).
Treatments, dosage schedule and rationale for dose
selection
The EMC Trial will use only established drugs in the
treatment of MDD. For the antidepressants escitalopram
and venlafaxine an equal efficacy in the acute-phase
treatment of MDD has been reported [31]. Both escita-
lopram and venlafaxine will be escalated to the partici-
pant’s highest tolerable dose, which (1) allows clinicians
to delay dose increases if the participant is initially intol-
erant; (2) approximates clinical practice; (3) allows some
initially intolerant participants to accommodate to a par-
ticular dose, subsequently permitting a dose increase
with an acceptable side effect burden; and (4) allows
participants with concurrent general medical conditions
to be retained in the trial while also receiving adequate
doses.
Escitalopram
Escitalopram is a selective serotonin reuptake inhibitor
and is licensed for the treatment of major depressive
episodes by national and international federal drug
agencies worldwide. In the treatment of MDD, escitalo-
pram is an established first choice drug. There is evi-
dence suggesting a statistically significant difference
favouring escitalopram over other antidepressants [10].
A fixed-dose-study showed a slightly better outcome in
patients with 20 mg escitalopram/d compared to
patients treated with 10 mg/d, suggesting a higher effi-
cacy of 20 mg/d, particularly in patients with severe
depression [32]. In order to achieve maximal effective-
ness, escitalopram will be titrated to 20 mg/d according
to its German federal license for the treatment of MDD.
Escitalopram should be administered at 10 mg on day 1
and at 20 mg on day 2 and onwards. Escitalopram
should be administered in the morning and once daily.
Dose adjustments, e.g. dose reduction in case of side
effects, are allowed.
Venlafaxine
Venlafaxine is a selective serotonin reuptake inhibitor at
75 mg/d and dual acting antidepressant (norepinephrine
and serotonin transporter inhibition) at doses of 150 mg
and above. At higher doses it also inhibits dopamine
reuptake. It is licensed by national and international fed-
eral drug agencies worldwide for the treatment of major
depressive episodes. The results of numerous meta-ana-
lyses of the efficacy data for venlafaxine support the
conclusion that venlafaxine is a superior antidepressant
[33]. The switch from selective serotonin reuptake inhi-
bitor to venlafaxine after treatment failure is supported
by a meta-analysis of 3 randomised controlled trials
showing the superiority of the switch to venlafaxine ver-
sus another selective serotonin reuptake inhibitor [34].
Available dose finding studies showed a positive dose-
response relationship for venlafaxine in the treatment of
MDD with a superior efficacy at 375 mg/d compared to
225 mg/d, 150 mg/d, 75 mg/d, and placebo [35]. In
order to achieve maximum effectiveness, venlafaxine will
be titrated to max. 375 mg/d according to its German
federal license for the treatment of MDD. Venlafaxine
should be administered at 75 mg on day 1, at 150 mg
on day 2, at 300 mg on day 3 and at 375 mg on day 4.
Venlafaxine should be administered in the morning and
once or twice daily. Dose adjustments, e.g. dose reduc-
tion in case of side effects, are allowed.
Lithium augmentation
Lithium augmentation is by far the most often studied
strategy in depressed patients with insufficient
response to an antidepressant (27 open and 10 rando-
mised placebo-controlled trials). A recent meta-analysis
of these 10 randomised controlled trials showed that
lithium had a positive effect versus placebo, with an
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needed to treat of 5. The mean response rate was
41.2% in the lithium group and 14.4% in the placebo
g r o u p( p<. 0 0 1 )[ 3 6 ] .I nt h eE M Ct r i a ll i t h i u md o s e
will be strictly adjusted according to the established
plasma level range of 0.6-0.8 mmol/l for the treatment
of MDD [15,37]. Lithium should be administered at 12
mmol on day 1 and at 24 mmol on day 2. Lithium can
be administered in the morning or in the evening and
once or twice daily. Dose adjustments, e.g. dose reduc-
tion in case of side effects, are allowed. After 1 week
of lithium treatment, plasma concentration will be
determined weekly. Dose adjustments will be per-
formed to reach the target plasma concentration of
0.6-0.8 mmol/l.
Concurrent medication
In general, the principles guiding the prohibition and
permission of additional treatments try to balance the
need to minimise the confounding effects of treatments
that may alter the effect sizes of treatments under study
with the goals of increasing the feasibility of conducting
a randomised treatment protocol and of increasing
treatment adherence among participants. By allowing
many additional treatments that are widely used in
practice, the EMC Trial enhances both generalisability
and feasibility. Additional pharmacotherapy will be
allowed to treat transient associated symptoms (e.g.,
insomnia) or transient medication side effects (e.g., agi-
tation or anxiety); i.e. short-acting sedatives (zolpidem
or zopiclone), the low potency neuroleptic drug pipam-
perone, the histamine-receptor antagonist promethazine
in standard doses as well as benzodiazepines in a dose-
equivalent to max. 15 mg of diazepam. Participants
may receive treatment for concurrent general medical
conditions, as long as these medications do not contra-
indicate the use of protocol medications. Any antide-
pressant medication taken at study entry must be
discontinued (after consent) before beginning escitalo-
pram. Appropriate wash-out will be assured by determi-
nation of plasma drug concentration. Not permitted
drugs for the entire duration of the EMC trial are drugs
that are contraindicated during the treatment with one
of the three protocol medications. These drugs are: i)
irreversible non-selective inhibitors of the monoamino-
oxidase (MAO); ii) the reversible, selective MAO-A
inhibitor moclobemide; iii) the reversible, non-selective
MAO-inhibitor linezolide; iv) the irreversible, selective
MAO-B-inhibitor selegiline; v) other antidepressant
drugs; vi) antipsychotic drugs; vii) mood-stabilizing
agents other than lithium. Furthermore, not permitted
drugs for the entire duration of the EMC Trial are
drugs with substantial influence of the major endpoints
of the study.
Procedures for monitoring subject compliance
Trial medication will be dispensed to the subjects by
the investigator. During hospitalisation the medication
w i l lb ed i s t r i b u t e db yas t u d yn u r s ea n dt h ep a t i e n t ’s
compliance will be assessed by counting of unused
tablets. Additionally, compliance will be assessed by
therapeutic drug monitoring (TDM). In case of out-
patient treatment (i.e., in case of demission from hospi-
tal during the study), subjects will be instructed to
bring all trial medication to the trial site at every visit
(including all empty packages and unused trial medica-
tion). Compliance will be assessed by counting of
unused tablets and TDM.
Measurements/Trail Schedule
For an overview of the measurements of the EMC Trial,
see the trial schedule (Figure 2).
Assessment of efficacy
Assessment of efficacy comprises symptomatic and
functional changes from screening or baseline to study
end in weekly intervals. Symptom changes will be
assessed by the HAMD17. Additionally, depression
severity will be assessed with the 30-items clinician-
rated version of the Inventory of Depressive Symptoma-
tology (IDS-C30). These interviews will be performed by
trained raters. The IDS is also available as a self-rating
instrument (IDS-SR30). It will be used to evaluate the
patients’ perspective of symptom severity. Patients’ func-
tion will be assessed using the Short-Form Health Sur-
vey as a measure for health-related quality of life
independent of psychiatric diagnosis. Its 12-item version
assesses the two dimensions “physical health” and “psy-
chic health” as subscales. Each item refers to a different
symptom concerning either “physical health” or “psychic
health”. The interview will be performed by trained
raters. Raters will be blind to randomization in order to
prevent assessment bias. The Short-Form Health Survey
is also available as a self-rating instrument. It will be
used to evaluate the patients’ perspective of impaired
function.
Assessment of safety
Definitions Adverse events (AE), serious adverse events
(SAE), and serious adverse reactions (SAR) as well as
suspected unexpected serious adverse reactions
(SUSAR) are defined are according to the Guideline for
Good Clinical Practice of the International Conference
on Harmonisation (ICH-GCP) in its current version
(CPMP/ICH/135/95/Step 5, ICH Topic E6 (R1); http://
www.ema.europe.eu).
Assessment of AEs by the investigator AEs will be
assessed by the investigator in weekly intervals (see fig-
ure 2). Additionally, inpatients will receive daily clinical
visits by the ward physician; in case of a new symptom
the investigator will be contacted in order to decide
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Action 
SC  BL  V1  V2  V3  V4  V5  V6  V7  V8 
Trial day  -7±2 0  7±2 14±2 21±2 28±2 35±2 42±2  49±2  56±2
Basic documentation  X 
Inclusion/exclusion criteria  X                   
Patient information and 
consent  X             
Demographics  X             
Diagnostic procedures  X 
X . I . N . I . M
X I I - D I C S
Treatment history  X                   
Psychiatric history  X                   
Medical  history  X             
Physical status 
Physical  examination  X             
X S R I C
Vital  signs  X  X  X  X X X X X X X 
Electrocardiography  X        X      X 
Randomisation 
Randomisation in level 1        X             
Treatment change in non-
responders in level 2          X        
Randomisation in level 2 and 
3            X
Treatment outcome 
X X X X X X X X X X 7 1 D M A H
X X X X X X X X X X 0 3 C - S D I
IDS-SR30  X  X  X  X X X X X X X 
SF-12  (clinician  rating)     X  X  X X X X X X X 
SF-12  (self-rating)   X  X  X X X X X X X 
Safety 
Adverse  event  monitoring   X  X  X X X X X X X 
X X X X X X X X X U K U
Laboratory measures 
Routine  laboratory  X  X    X  X  X  X 
Pregnancy test in females  X                   
CPL of pre-medication
§   X                 
CPL of  trial  medication      X  X X X X X X X 
Creatinine clearance
§§           X    X     
End of trial  X 
Figure 2 Schedule of The EMC Trial.
§ in case of existing pre-medication to assure complete wash-out;
§§ in case of lithium treatment;
Abbreviations: BL (baseline visit); CIRS: Cumulative illness Rating Scale; CPL (plasma concentration); HAMD17 (17-item Hamilton-Depression-
Rating-Scale); IDS-C30 (30-item Inventory of Depressive Symptomatology); SC (screening visit); M.I.N.I. (Mini International Neuropsychiatric
Interview); SCID-II (Structured Clinical Interview for DSM-IV Axis II Disorders); SF-12 (12-item Short Form Health Survey); UKU (Udvalg for Kliniske
Undersogelser).
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SAE, SAR or SUSAR. Adverse events will be assessed in
terms of their seriousness, severity, and relationship to
the study drug.
Period of observation In this trial, the period of obser-
vation for collection of adverse events extends from the
time the subject has signed the informed consent docu-
ment up to study day 56 (end of the trial). All subjects
who have adverse events, whether considered associated
with the use of the investigational products or not, must
be monitored to determine the outcome. The clinical
course of the adverse event will be followed up accord-
ing to accepted standards of medical practice, even after
the end of the period of observation, until a satisfactory
explanation is found or the investigator considers it
medically justifiable to terminate follow-up, but no
longer than 30 days after the end of the trial. Should the
adverse event result in death, a full pathologist’sr e p o r t
should be supplied, if possible. If the investigator detects
a serious adverse event in a trial subject after the end of
the period of observation, and considers the event possi-
bly related to the prior trial, he should contact the spon-
sor to determine how the adverse event should be
documented and reported.
Documentation of AEs All AEs (whether serious or
non-serious) reported by the subject or detected by the
investigator will be documented on the “Adverse Event”
pages of the CRF. AEs will also be documented in the
subject’s medical record. If the adverse event is serious
(see below), the investigator must complete, in addition
to the “Adverse Event” page, a “Serious Adverse Event”
f o r mi nt h eI S Fa tt h et i m et h eS A Ei sd e t e c t e d .T h i s
form must be immediately sent to responsible SAE
Management of the independent Interdisciplinary Cen-
tre for Clinical Trials (IZKS) at the University Medical
Center Mainz. Every attempt will be made to describe
the adverse event in terms of a diagnosis. If a clear diag-
nosis has been made, individual signs and symptoms
will not be recorded unless they represent atypical or
extreme manifestations of the diagnosis, in which case
they should be reported as separate events. If a clear
diagnosis cannot be established, each sign and symptom
must be recorded individually.
Immediate reporting by investigator SAEs must be
reported immediately within 24 hours after the SAE
becomes known to IZKS Mainz. The initial SAE Report
must be as complete as possible including details of sub-
ject’s identification (screening number, random num-
ber), the (serious) adverse event (medical term,
diagnosis), the trial medication and an assessment of the
causal relationship between the event and the trial medi-
cation made by the investigator. The investigator should
provide related additional information on the clinical
course and the outcome of each SAE as soon as possible
to IZKS Mainz using the SAE form (Follow up report).
In addition, any pregnancy diagnosed in a female subject
or in the female partner of a male subject during treat-
ment with the investigational product must be reported
to the sponsor immediately via facsimile using the SAE
form. Worsening of a sign or symptom of the condition
under treatment will normally be measured by efficacy
parameters. However, if the outcome fulfils the defini-
tion of “serious adverse event”,i tm u s tb er e p o r t e da s
such.
Safety evaluation by sponsor According to GCP the
sponsor is responsible for the continuous safety evalua-
tion of the investigational product(s) and the clinical
trial. On behalf of the sponsor, IZKS Mainz will conduct
the management of SAEs and the expedited reporting as
required by German Drug Law (AMG) and GCP regula-
tion (GCP-V). Suspected unexpected serious adverse
reactions (SUSARs) and safety issues as defined by
GCP-V are determined for expedited reporting: The
competent authorities and the ethics committees should
be notified as soon as possible but not later than 15
calendar days if the event is non-fatal and 7 calendar
days if it was fatal. All investigators should be informed
too. Work flow and procedures concerning SAE man-
agement will be described in a safety manual. During
the clinical trial the sponsor will submit the annual
safety report including a list of all serious adverse reac-
tions to the ethics committee(s) and the competent
authorities once a year. A Data and Safety Monitoring
Committee (DSMC) is established to supervise the clini-
cal trial (see below).
Other safety data All observations pertinent to the
safety of the study medication will be recorded on the
CRF and included in the final report. Safety variables
are as follows: UKU scale, laboratory changes (panels for
electrolytes, creatinine, liver enzymes, haematology,
creatinine, creatinine clearance in case of lithium treat-
ment), changes in vital signs (blood pressure, heart rate
and temperature) and, cardiologic evaluation by ECG.
The UKU scale and recording of vital signs will be per-
formed in weekly intervals; routine laboratory will be
collected in bi-weekly intervals; ECG will be performed
in four-week intervals.
Statistics
Details of the statistical analysis of the data collected in
this trial will be documented in a Statistical Analysis
Plan (SAP) that will be generated by IZKS Mainz and
finalized before closing the data base. The SAP is based
on the protocol including all amendments. The docu-
ment may modify the plans outlined in this protocol;
however any major modifications of the primary end-
point definition and/or its analysis will also be reflected
in a protocol amendment. Any deviation from the
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the final report. The statistical analysis will be con-
ducted by means of SAS®.
Sample size
The sample size has been calculated for level 1 of the
EMC Trial (see Fig. 1 for trial design). For TAU 1,
non-improvers on day 14 continuing medication are
expected to become non-responders on day 28 in
about 88% and responders in 12% [25]. The switch
from escitalopram to venlafaxine led to a remission in
24% after 14 weeks of treatment [38]; for the treatment
period of this trial (day 29-56), we assume a remission
rate of 20% on day 56 for TAU 1. Responders on day
28 continuing medication are expected to become
remitters on day 56 in 75% [25], resulting in an
expected overall remission rate of 26% for TAU 1. In
the EMC 1 arm, non-improvers on day 14 switched to
venlafaxine are expected to show improvement in 70%
and non-improvement in 30% [24,25] after 14 days of
treatment, i.e. on study day 28. Improvers after 14 days
(i.e. study day 28) continuing venlafaxine medication
are estimated to become remitters in 55% [24,25];
lithium augmentation in non-improvers on study day
28 is expected to lead to a remission rate of 34% [39].
Taken together, an overall remission rate of 49% on
day 56 is estimated for EMC 1. A drop out rate of 12%
is assumed; drop-outs will be classified according to
the last available HAMD17 sum score whereby
HAMD17 scores before day 28 will not be carried for-
ward. Patients with no HAMD17 score available from
d a y2 8u n t i ld a y5 6w i l lb ec o n s i d e r e da sn o n - r e m i t -
ters. Hence, remission rates of 49% and 26% in the
underlying population correspond to 43% and 23% if
12% of dropouts are counted as non-remitters. These
proportions result in an odds ratio of 2.5 and require
sample sizes of 96 patients per group (alpha = 0.05,
Fisher’s exact test, 2-sided) for a power of 80%. There-
fore, it is planned to randomise 192 patients of non-
improvers on day 14. As of 30% of patients enrolled in
the study are expected to be non-improvers after 14
days of escitalopram treatment, 640 patients (= ITT
s a m p l e )h a v et ob ee n r o l l e di nt h es t u d ya n d1 2 8 0
patients must be screened under the assumption that
50% are willing to participate.
Analysis populations
All subjects who signed informed consent are consid-
ered as enrolled subjects, even if they did not receive
any trial treatment. The Intention-to-treat (ITT) popu-
lation comprises all enrolled subjects. Within ITT popu-
lation analyses, subjects will be assigned to the
treatment to which they were randomised. To be eligi-
ble for the per protocol (PP) population, subjects must
fulfil the following criteria: i) all visits have been per-
formed; ii) each visit has been performed according to
visit schedule; iii) treatment compliance of at least 90%
measured by drug accountability. Additional criteria will
be defined during the conduct of the trial and before
database closure. The safety population comprises all
subjects who received at least one dose of trial treat-
ment. In analyses of the safety population, subjects will
be assigned to the treatment which they actually
received. The analysis populations will be defined prior
to the database closure. Within the ITT and PP popula-
tion the following sub-collectives will be defined (see
also figure 1):
Level 1 ￿ Non-improvers on day 14 = EMC1 + TAU1.
These patients of the ITT sample represent the analysis
population of the primary endpoint.
Level 2 ￿ Improvers on day 14, who are non-responders
on day 28 and non-improvers on d42 = EMC 2 + TAU
2
￿ Improvers on day 14, who are non-responders on
day 28 and have venlafaxine treatment from day 43 to
endpoint = TAU 2 + IML 2
Level 3 ￿ Responders on day 28, who are non-improvers
on day 42 = EMC 3 + TAU 3. Remitters on d42 will be
counted as improvers regardless of the HAMD17 total
score change from d28-42.
￿ Responders on day 28, who have escitalopram treat-
ment from day 43 to endpoint = TAU 3 + IML 3
Other ￿ Dropouts before a possible randomisation
Efficacy analyses
The primary analysis population of the primary end-
point is the ITT Population of non-improvers on day 14
(level 1 of the EMC trial). All hypotheses will be tested
on a two-sided level of significance a = 0.05.
Analysis of primary endpoint
The primary endpoint is remission from MDD, defined
as a HAMD17 sum score ≤ 7, on day 56 in non-impro-
vers on day 14. The null hypothesis to be tested is:
H0:R R D 5 6 EMC =R R D 5 6 TAU vs. Ha: RRD56EMC ≠
RRD56TAU
RRD56 denotes the remission rates on day 56 in the
respective treatment group. It is assumed that remis-
sion rates are higher in the EMC 1 group. The hypoth-
esis will be tested by Fisher’s exact test using a two-
sided significance level of 0.05. Additionally a 95%
confidence interval for the difference in remission
rates will be calculated. In the primary analysis
HAMD17 sum scores will be carried forward from day
28 on. Patients with no HAMD score available between
day 28 and 56 will be classified as non-remitters. This
approach is rather conservative; however, in our opi-
nion it is justified, because all of these patients are
non-improvers at week 2 and it is likely that these
patients would have become final non-remitters after
being non-improver at week 2. Missing data patterns
are not expected to differ between treatment groups
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are quite a few methods for multiple imputation avail-
able; the choice of the appropriate method depends on
several factors including the missing value pattern.
Here, we prefer a method for replacing missing data
that can be unambiguously specified in advance which
is essential in confirmatory trials. Nevertheless, we will
incorporate an analysis imputing missing values multi-
ply as a further sensitivity analysis. The analysis of the
primary endpoint will be repeated for the Per-Proto-
col-Population comprising all non-improvers on day
14 with a minimum of adherence to the trial protocol
in a descriptive way. As a secondary analysis, a logistic
regression of remission on treatment group, trial site,
sex, baseline severity of depressive symptoms, comor-
bid disorders, plasma concentrations of ADs and addi-
tional treatments will be performed.
Analysis of secondary endpoints
Remission according to HAMD17 (definition see pri-
mary endpoint) in all ITT and PP sub-collectives of
level 2 and 3.
The following secondary endpoints will be analyzed
separately for the ITT and PP sub-collectives of level 1,
2 and 3 defined above:
￿ The comparison of response rates to AD treatment
defined as HAMD17 sum score decrease of at least 50%
on day 56, and remission rates according to IDS will be
analysed in the same way as the primary endpoint.
￿ Absolute change in HAMD17 sum scores will be
analyzed using a two sample t-test.
￿ Remission/response according to IDS will be ana-
lyzed in the same way as the corresponding HAMD17
analyses.
￿ Comparison of time to remission and time to
response will be analyzed by means of life table
estimates.
￿ Absolute change in SF-12 scores will be analyzed
using a two sample t-test.
All analyses of secondary endpoints will be interpreted
exploratory. Corresponding 95% confidence intervals for
the estimated parameters will be calculated. Descriptive
statistics will be displayed for all parameters.
Analysis of adverse events
All summaries and listings of safety data will be per-
formed for the safety population. Frequencies of sub-
jects experiencing at least one adverse event (AE) will
be displayed by body system and preferred term
according to MedDRA terminology. Detailed informa-
tion collected for each AE will include: A description
of the event, duration, whether the AE was serious,
intensity, relationship to trial drug, action taken, clini-
cal outcome. Summary tables will present the number
of subjects observed with AEs and corresponding per-
centages. Additional subcategories will be based on
event intensity and relationship to trial drug. A subject
listing of all AEs will be prepared. UKU ratings col-
lected at every visit starting at baseline will be pre-
sented in a way that changes in the course of the
study can be identified.
Analysis of clinical laboratory findings, ECG values and vital
signs
Listings will be prepared for each laboratory measure
and will be structured to permit review of the data per
subject as they progress on treatment. Summary tables
will be prepared to examine the changes of laboratory
measures over time. Additionally, shift tables will be
provided to examine the changes of laboratory data
from normal baseline to values outside the correspond-
ing reference range during/after treatment.
Ethical aspects
Good clinical practice
The procedures set out in this trial protocol, pertaining
to the conduct, evaluation, and documentation of this
trial, are designed to ensure that all persons involved in
the trial abide by good clinical practice (GCP) and the
ethical principles described in the Declaration of Hel-
sinki. The trial will be carried out in accordance with
local legal and regulatory requirements. The require-
ments of the AMG, the GCP regulation, and the Federal
Data Protection Law (BDSG) will be kept. The trial was
approved in July 2009 by the ethics committee at the
Landesärztekammer Rheinland-Pfalz (code: 837.211.09
(6717)).
Summarized risk-benefit assessment
All drugs used within the EMC Trial are established in
the treatment of major depression and licensed by
national and international federal drug agencies world-
wide for the treatment of major depression. Relying on
current treatment guidelines, it is standard care to con-
tinue treatment in patients without improvement in the
early course of treatment. This strategy has to be ques-
tioned in the light of the substantial data basis support-
ing the view that non-improvement predicts poor later
outcome. Thus, the EMC trial will provide answers to
this important question.
Data and Safety Monitoring Committee (DSMC)
The trial is supervised by a data and safety monitoring
committee that consists of one Chair of a University
Department of Psychiatry in Germany with substantial
experience in clinical trials, one clinical pharmacologist
with special experience in pharmacovigilance and one
biometrician, who is head of an University Institute of
Medical Statistics, Informatics and Epidemiology in Ger-
m a n y .T h i sD S M Cs u p e r v i s e st h ep r o g r e s so ft h et r i a l ,
monitors the safety data, reviews all relevant information
on the trial topic from all other sources, ensures adher-
ence to the protocol, advices whether to continue,
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nisations with information and advice in accordance
with the DSMC Standard Operating Procedure. The
DSMC meetings will be held once a year.
Discussion
The EMC trial is unique because it investigates for the
first time prospectively whether MDD patients with
non-improvement after 14 days of AD treatment with
EMC are more likely to become remitters compared to
patients treated according to current guidelines, i.e.,
with a medication change after 28 days of treatment in
case of non-response. All current evidences originate
from retrospective data analysis, but not from prospec-
tive clinical trials: there is substantial evidence showing
that non-improvement in the first 2 weeks of AD treat-
ment is highly predictive for poor final outcome and
leading experts in the field have repeatedly recom-
mended the outcome evaluation in the early course of
treatment as well as the consideration of early symptom
changes in clinical decision making [23-27]. However,
the entire knowledge about the predictive value of early
improvement derives exclusively from retrospective data
analyses. No study has yet prospectively investigated
whether non-improvers (HAMD17 decrease <20%) after
14 days of AD treatment with EMC are more likely to
become remitters compared to patients with a medica-
tion change after 28 treatment days in case of non-
response (HAMD17 decrease <50%). Thus, the EMC
trial is indispensable to prove the clinical value of early
improvement and to realise the transfer from retrospec-
tive analyses to convincing prospective clinical trials. If
our hypothesis holds true that the EMC strategy leads
to a relevantly higher proportion of remitted patients,
this could have a substantial impact on various aspects
of MD treatment, e.g. patients’ welfare, clinical guide-
lines, daily clinical practice, economic costs of MD as
well as research settings.
The protocol of the EMC trial schedules in level 1 a
randomization step for non-improvers two weeks after
treatment start. This approach focuses on a patient
g r o u pt h a ti sa th i g hr i s kf o rt r e a t m e n tf a i l u r e .T h e
same approach has been applied in levels 2 and 3 of the
EMC trial, where randomization steps are scheduled for
patients who experience no further symptom ameliora-
tion after an initial improvement or response, respec-
tively. This approach represents an advantage compared
to other possible designs such as randomising all partici-
pants at baseline to TAU vs. EMC. Such a design would
be inappropriate, because it would randomize patients
with a favourable treatment outcome to the first antide-
pressant medication to both EMC and TAU. There is
no need for the evaluation of an EMC strategy in
patients with a continuous and favourable treatment
outcome, because there is no indication for a treatment
change in these patients. Furthermore, such a design
would erroneously diminish the effect size of the EMC
strategy compared to TAU.
The design of the EMC trial schedules as primary
outcome “remission at day 56” after treatment start.
This is a common duration in antidepressant treatment
trials. However, after an initial improvement the con-
tinuous amelioration of symptoms and finally the
development of remission might exceed the time per-
iod of 6 weeks (e.g. after the start of venlafaxine treat-
ment on day 15 in EMC 1), or 4 weeks (e.g. after the
augmentation of venlafaxine with lithium in EMC 1 or
after the start of venlafaxine treatment in TAU 1).
Therefore, the remission rates obtained in subgroups
of the EMC trial might be lower compared to a design
that would schedule a primary endpoint at week 10 or
12 weeks after treatment start. However, this applies to
both EMC and TAU strategy and there is no reason to
expect differences in the speed of the development of
remission after an initial improvement between groups.
Therefore, the design of the EMC trial is economic
and meaningful with regard to the primary efficacy
measure “remission”.
Very long treatment duration requires substantial
patience and adherence from depressed patients, which
is particularly difficult, when pessimism and hopeless-
ness dominate the outlook of these patients. Ineffective
therapy is especially problematic in MD because it can
i n c r e a s et h er i s kt h a tp a t i e n t sl o s ec o n f i d e n c ei na n d
detach from their treating physicians, stop taking their
prescribed medication, or lose hope that their symptoms
can be effectively treated. As a result, the risk of serious
complications, such as suicide, is increased.
Current national and international clinical guidelines
usually do not contain recommendations for adapting
an individual’s treatment during the early course of
therapy, but schedule a treatment duration between 2-
4 weeks [14], 3-4 weeks [15,16], 4-6 weeks [17], 4-8
weeks [18] until insufficient outcome is diagnosed and
treatment optimisation is recommended. Furthermore,
recommendations for the optimal duration of treat-
ment until identification of insufficient outcome vary
from guideline to guideline and are not based on pro-
spective clinical trial evaluating the effectiveness of dif-
ferent treatment strategies, but on retrospective data
analysis reflecting the assumption of a delayed onset
hypothesis. On the other hand, acknowledging the
growing data basis that non-improvement is highly
predictive for final treatment outcome, more recent
guidelines [14-16] have already shortened the time
span until treatment optimisation in case of insuffi-
cient outcome compared to older ones [17,18]. How-
ever, although significant data basis suggests that
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weeks, guidelines have not yet included a regularly
treatment optimization after two weeks. This is entirely
justified because of the lack of a prospective clinical
trial. The EMC Trial will close this significant gap in
depression research. If our hypothesis holds true that
the EMC strategy leads to a relevantly higher propor-
tion of remitted patients, guidelines for the treatment
of MDD could implement recommendations for
adjusting an individual’s treatment regularly during the
early course of therapy, i.e., within the first 2 weeks of
treatment.
Early and continued monitoring of treatment outcome
is no standard application in clinical practice: Superior-
ity of the EMC strategy could change clinical practice
profoundly. Clinicians would be prompted to optimise
their treatment in case of non-improvement after 2
weeks because of clear evidence that non-improvers
with an early treatment optimisation would be more
likely to become remitters compared to those patients
with continued medication. Early and continued moni-
toring of treatment outcome would become a standard
application in MDD treatment because it can be easily
implemented in the clinical setting. It does not require
expensive technical investment and can be applied
worldwide. Implementation only requires an assessment
of depression severity at baseline and at weekly intervals
with an adequate scale. Given the potential for saving
time and costs by using early improvement as a predic-
tor of later outcome, a weekly investment of 15-20 min-
utes for the rating of depressive symptoms would be
reasonable.
The economic effects of EMC could be substantial
since patients could be cured from depression in a
shorter period of time, which could decrease direct and
indirect costs associated with MDD. Furthermore, this
could substantially decrease the duration of prescrip-
tions of antidepressants with limited effectiveness for
the individual patient. The continued prescription of an
inefficient drug can result in a substantially prolonged
treatment duration, which highly increases resource use.
However, the evaluation of the economic effects of the
EMC strategy compared to TAU is not the main focus
of the EMC trial. The selected instruments SF-12 as
clinician and self report interview will allow the assess-
ment of differences in quality of life between EMC and
TAU. Furthermore, exploratory analyses like the calcula-
tion of differences in the duration of hospital treatment
between EMC and TAU will give first suggestive infor-
mation on the economic effects of EMC strategy. Stu-
dies for the comprehensive analysis of the economic
effects of an EMC strategy in major depression should
be conducted in case of a proven clinical superiority of
EMC vs. TAU.
In research settings the typical duration of trials for
the evaluation of ADs’ efficacy is between 4-8 weeks, or
even longer. E.g., the STAR*D trial has been conducted
with a duration of a single medication for up to 14
weeks [[9], and references inside]. In MDD, more
research trials for the evaluation of antidepressants’ effi-
cacy would use a shorter period than the 4-8 weeks cur-
rently regarded as appropriate. The EMC strategy would
be extended to other antidepressants in the treatment of
MDD. Additionally, the evaluation of the EMC strategy
would likely be extended to other major psychiatric dis-
orders like schizophrenia or generalised anxiety disorder.
Regarding schizophrenia, it has been shown that a true
drug response to antipsychotic pharmacotherapy can be
observed within 2 weeks of treatment [40,41]. Regarding
generalised anxiety disorder, retrospective analysis of
time courses of response to drugs with largely different
pharmacologic profiles (duloxetine, benzodiazepines,
and serotonin receptor 1A partial agonist) showed that
early improvement of anxiety symptoms was highly pre-
dictive of later outcome [42].
As described above, current guidelines recommend a
treatment optimization after4w e e k si nc a s eo fi n s u f f i -
cient outcome (<50% symptom reduction) after 4 weeks
of treatment [15]. After this treatment optimisation step,
there are no further recommendations on the appropri-
ate monitoring or further measures for treatment opti-
misation. Therefore, the EMC trial will be able to give
valuable information regarding this significant gap in
the knowledge about depression treatment. Level 2 of
the EMC trial addresses patients, who show an initial
improvement, but do not experience a response after 4
weeks of treatment. For these patients, current guide-
lines recommend a treatment optimisation. These
recommendations will be adhered to by a switch to ven-
lafaxine treatment. After this, guidelines do no include
recommendations on the monitoring or further treat-
ment optimisation steps in the course of treatment.
Therefore, we will apply an EMC strategy (EMC 2) and
a standard strategy (TAU 2) to patients not improving
after 2 weeks of venlafaxine treatment. Level 3 of the
EMC trial addresses patients, who show an initial
improvement, experience a response after 4 weeks of
treatment, but get stuck in their symptom amelioration
between weeks 4 and 6 of treatment. For these patients,
current guidelines do not contain any treatment recom-
mendation. Therefore, we will apply an EMC strategy
(EMC 3) and a standard strategy (TAU 3) to these
patients.
In summary, The EMC Trial will provide evidence
regarding substantial questions in the treatment of
major depression. Superiority of the EMC strategies
compared to the respective TAU strategies could have
substantial impact on patients’ welfare, clinical
Tadić et al. Trials 2010, 11:21
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Page 15 of 17guidelines, daily clinical practice, and economic costs of
MD as well as research settings.
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